UBS Group’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $341M | Sell |
|
|||||
|
2025
Q1 | $584M | Buy |
|
|||||
|
2024
Q4 | $322M | Buy |
|
|||||
|
2024
Q3 | $174M | Buy |
|
|||||
|
2024
Q2 | $157M | Sell |
|
|||||
|
2024
Q1 | $180M | Sell |
|
|||||
|
2023
Q4 | $224M | Buy |
|
|||||
|
2023
Q3 | $126M | Buy |
|
|||||
|
2023
Q2 | $107M | Sell |
|
|||||
|
2023
Q1 | $103M | Buy |
|
|||||
|
2022
Q4 | $108M | Sell |
|
|||||
|
2022
Q3 | $212M | Sell |
|
|||||
|
2022
Q2 | $302M | Buy |
|
|||||
|
2022
Q1 | $188M | Sell |
|
|||||
|
2021
Q4 | $286M | Buy |
|
|||||
|
2021
Q3 | $185M | Sell |
|
|||||
|
2021
Q2 | $272M | Buy |
|
|||||
|
2021
Q1 | $264M | Sell |
|
|||||
|
2020
Q4 | $388M | Buy |
|
|||||
|
2020
Q3 | $254M | Buy |
|
|||||
|
2020
Q2 | $228M | Buy |
|
|||||
|
2020
Q1 | $152M | Sell |
|
|||||
|
2019
Q4 | $208M | Sell |
|
|||||
|
2019
Q3 | $170M | Sell |
|
|||||
|
2019
Q2 | $483M | Sell |
|
|||||
|
2019
Q1 | $738M | Buy |
|
|||||
|
2018
Q4 | $573M | Buy |
|
|||||
|
2018
Q3 | $287M | Sell |
|
|||||
|
2018
Q2 | $411M | Buy |
|
|||||
|
2018
Q1 | $200M | Sell |
|
|||||
|
2017
Q4 | $256M | Buy |
|
|||||
|
2017
Q3 | $137M | Sell |
|
|||||
|
2017
Q2 | $130M | Sell |
|
|||||
|
2017
Q1 | $254M | Buy |
|
|||||
|
2016
Q4 | $118M | Sell |
|
|||||
|
2016
Q3 | $171M | Buy |
|
|||||
|
2016
Q2 | $113M | Buy |
|
|||||
|
2016
Q1 | $96.7M | Sell |
|
|||||
|
2015
Q4 | $201M | Sell |
|
|||||
|
2015
Q3 | $222M | Buy |
|
|||||
|
2015
Q2 | $254M | Buy |
|
|||||
|
2015
Q1 | $205M | Buy |
|
|||||
|
2014
Q4 | $109M | Buy |
|